ICU Medical
Builds infusion pumps, IV consumables, and vital-care devices for clinical workflows.
Something off on this page? Send us feedback.
Profile
Supplies hospitals and other care settings with IV consumables, infusion pumps and software, and vital-care devices, generating revenue from product and service sales. Operates as one segment, while sterile IV solutions are sold and distributed through its Otsuka joint-venture relationship.
Develops and manufactures infusion therapy, vascular access, and vital-care products for hospitals, clinics, home-care providers, and long-term-care facilities. Consumables include IV sets, needlefree connectors, catheters, hazardous-drug transfer systems, and tracheostomy products. Infusion Systems pairs large-volume, syringe, and ambulatory pumps with dedicated sets, medication-safety software, and professional services. Vital Care covers anesthesia, respiratory, hemodynamic monitoring, temperature-management, and pain-management products.
Sells worldwide through direct teams and distributors, with the portfolio managed as one reportable segment. Pump platforms and their dedicated disposables support integrated medication-delivery workflows. Sterile IV solutions are distributed for the Otsuka ICU Medical joint venture rather than owned as a controlled business. Medical-device approvals and quality systems govern commercialization; manufacturing is concentrated in the United States, Costa Rica, Mexico, and the Czech Republic, with some components sourced from single or limited suppliers.
Company facts
Categories
Key statistics
Year to date +26.4% · Average volume (30d) 301.4K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | Needham | Reiterate | Buy | $165 | $187 | |
| Aug 7, 2026 | BTIG | Reiterate | Buy | $170 | $200 | |
| Aug 7, 2026 | Raymond James | Reiterate | Strong Buy | $97 | $200 | |
| Jul 21, 2026 | KeyBanc | Reiterate | Overweight | $164 | $182 | |
| Jun 15, 2026 | BTIG | Target | $170 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | $1.91 | $2.37 | +24.1% | $533.4M | $547.9M | +2.7% | +10.93% |
| May 7, 2026Q1 FY26 | $1.78 | $1.97 | +10.7% | $520.6M | $525.8M | +1.0% | +2.73% |
| Feb 19, 2026Q4 FY25 | $1.68 | $1.91 | +13.7% | $530.6M | $535.9M | +1.0% | +4.87% |
| Nov 6, 2025Q3 FY25 | $1.43 | $2.03 | +42.0% | $511.5M | $537.0M | +5.0% | +8.09% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $604.7M | $548.9M | $537.0M | $540.3M | $530.4M | $551.7M | |
| Gross profit | $210.1M | $208.1M | $200.9M | $202.1M | $173.1M | $235.1M | |
| Operating income | $12.9M | $10.6M | $13.7M | $25.2M | $30.7M | $39.1M | |
| Net income | −$15.5M | $35.3M | −$3.4M | −$15.7M | $30.1M | $19.1M | |
| Diluted EPS | −$0.63 | $1.43 | −$0.14 | −$0.64 | $1.20 | $0.76 | |
| Gross margin | 34.7% | 37.9% | 37.4% | 37.4% | 32.6% | 42.6% | |
| Operating margin | 2.1% | 1.9% | 2.6% | 4.7% | 5.8% | 7.1% |
Fiscal years (4-quarter sums)FY21 $1.32B · FY22 $2.28B · FY23 $2.26B · FY24 $2.38B · FY25 $2.23B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $298.3M · Total debt $1.27B · Total assets $3.97B · Shareholders' equity $2.15B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 24.99M · Float 24.50M · 98.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 3.75M | 15.02% | 13F | Aug 7, 2026 |
| Jupiter Topco LLC | 2.78M | 11.13% | 13F | Aug 14, 2026 |
| Janus Henderson Group PLC | 2.47M | 10.00% | 13G | Aug 14, 2025 |
| Vanguard Portfolio Management LLC | 1.47M | 5.88% | 13F | Aug 13, 2026 |
| Fuller & Thaler Asset Management, Inc. | 1.30M | 5.19% | 13F | Aug 12, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | Daniel Woolson | officer: VP, GM-Infusion Capital | −5,417 | $181.33 |
| Aug 12, 2026 | Ben Sousa | officer: Chief Information Officer | −2,250 | $178.32 |
| Aug 11, 2026 | Christian B. Voigtlander | officer: Chief Operating Officer | −8,929 | $182.93 |
| Aug 11, 2026 | Elisha W. Finney | director | −378 | $182.48 |
| May 22, 2026 | Daniel Woolson | officer: President | −2,123 | $132.21 |
Peers
- BD
Broad overlap in infusion systems, access, and monitoring
- Baxter International
Major IV therapy rival across pumps, fluids, and sets
- Teleflex
Vascular-access and acute-care consumables overlap
- Medtronic
Vital-care overlap in monitoring, airway, and warming
- AngioDynamics
Focused vascular-access and specialty-consumables rival
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ICU Medical | $175.10 | +0.01% | $4.38B | 148.4 | 19.7 | 2.0 | −0.2% |
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| Baxter International | $26.30 | +0.65% | $13.51B | — | 12.5 | 1.2 | +5.3% |
| Teleflex | $139.67 | −0.01% | $6.18B | — | 15.2 | 2.4 | −27.0% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| AngioDynamics | $15.85 | −0.06% | $655.1M | — | — | 2.0 | +8.1% |
| Median | 40.8 | 14.8 | 2.4 | +5.3% |